Introduction
Thromboembolic sequelae are a frequent cause of illness and death everywhere around the world. Venous tromboembolism is occurs in 100 -160 people out of 100 000 of total annually [1] .
Nowadays the most perspective medicine for thrombosis prevention is the direct anticoagulants -direct inhibitors II factor (dabigatranetexilate) [2] and X factor (apixaban, rivaroxaban) [3, 4] . However all these anticoagulants have certain disadvantages?
For example, bleedings of any localization, anemia, thrombocytopenia and liver dysfunctions are possible when using dabigatranetexilate. Contraindications to its use are severe renal insufficiency and liver dysfunctions [1, 5] .
When rivaroxaban was applied the following side effects, mentioned in the instruction for use, were identified -bleedings of any localization, anemia, thrombocytosis, tachycardia, hypotension, nausea, stool dysfunctions, stomachache, dry mouth, vomiting, increase in the activity of some enzymes, liver dysfunctions, dizziness, headache, faintings, renal insufficiency, itch, rash, extremity pain, fever, swellings andoverall deterioration of health. Contradictions to its use are bleedings, liver diseases, pregnancy, lactation period, child and teen age, severe renal insufficiency, lactose and galactose intolerance [4, 6] .
In the instruction for use to apixaban the following contradictions are stated: bleedings, liver diseases, renal dysfunctions, age below 18, pregnancy, lactation. The use of apixaban can cause anemia, thrombocytopenia, arterial hypotension, and bleedings of any localizations, nausea and liver dysfunctions [5, 6] .
Hence, the search for new compounds with direct anticoagulant activity is an urgent problem.
As the result of research into the compounds synthesized in Perm Satate Pharmaceutical Academy the new substance -Thiazoline Ammonium 4-Chlorophenyl-2-Hydroxy-4-Oxo-2-Butenoate, which significantly lengthens blood clotting time for rabbits and dogs in vitro, was discovered [7] . It acts in vivo upon intragastric and subcutaneous administration to rabbits [8] .
Therefore, the FS-169 can be administered orally and subcutaneously.
The aim of our research is to investigate the mechanism of action of the synthesized for the first time substance of Thiazoline Ammonium 4-Chlorophenyl-2-Hydroxy-4-Oxo-2-Butenoate (FS-169).
Materials and Methods
The research was conducted on purebred rabbits 2-4 kg of weight. The overall quantity of rabbits was 85.
Protocol number of the ethical committee which approved the research plan is №67 from 4 November 2012.
For the purposes of the research we used a «АPG4-02-P» coagulometer, a set of reagents for the Partial thromboplastin time
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The obtained results were processed by the Student-Fisher method [5] .
Results and their Discussions
During the study of the FS-169 influence on Ptt, prothrombin time and Thrombin time indicators the following results, presented in Table 1 , were obtained.
As is shown by the results, FS-169 substance effectively changes the prothrombin time and Ptt indicators. On the Thrombin time FS-169 has no influence. Therefore, FS-169 solute influences internal and external mechanisms of the I stage of coagulation -thromboplastin formation. The common factors of these mechanisms are II, V, and X. Thus we were able to identify the influence of FS-169 on the activity of these coagulation factors.
The obtained results are represented in diagram (Figure 1 ) and in Table 2 .
As is seen from the results, the substance does not influence the activity of II and V coagulation factors. FS-169 effectively is lowered the activity of X coagulation factor. The Thiazoline Ammonium 4-Chlorophenyl-2-Hydroxy-4-Oxo-2-Butenoate compound effectively changes the activity of X coagulation factor. 
